License Agreements - Lily (Details) - USD ($)	1 Months Ended	12 Months Ended			181 Months Ended
	Dec. 31, 2009	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2024
License agreements
Total revenues		$ 4,241,217,000	$ 3,695,649,000	$ 3,394,635,000
Eli Lilly
License agreements
Total revenues		0	0	70,000,000.0
Eli Lilly | OLUMIANT
License agreements
Total revenues		$ 135,600,000	$ 136,100,000	$ 134,500,000
Development Milestones | Eli Lilly
License agreements
Amount recognized and received for the achievement of a predefined milestone					$ 149,000,000.0
Development Milestones | Maximum | Eli Lilly
License agreements
Upfront and immediate milestone payment to be received under license agreement	$ 150,000,000.0
Regulatory Milestones | Eli Lilly
License agreements
Amount recognized and received for the achievement of a predefined milestone					335,000,000.0
Regulatory Milestones | Maximum | Eli Lilly
License agreements
Upfront and immediate milestone payment to be received under license agreement	365,000,000.0
Commercialization Milestones | Eli Lilly
License agreements
Amount recognized and received for the achievement of a predefined milestone					$ 50,000,000.0
Commercialization Milestones | Maximum | Eli Lilly
License agreements
Upfront and immediate milestone payment to be received under license agreement	$ 150,000,000.0